Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.65 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.65 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | PRKCB | P05771 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCH | P24723 | 1/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.48 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.47 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510614 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL30910033 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL7563995 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL8636551 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL303128 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4879843 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL30510651 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4204833 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL4294185 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 | |
| SCHEMBL7183039 | 0.98 | LPAR1 (0.68) | LPAR1LPAR3LPAR2DNM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210190799-A1 | METHOD FOR DIAGNOSING LIVER DISEASES AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR LIVER DISEASES USING CHANGES IN EXPRESSION OF TM4SF5 PROTEIN | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-06-24 | — | — | US | claimed |
| WO-2015042114-A1 | FERMENTATION PROCESS WITH DISTINCT GROWTH AND PRODUCTION STAGES | NOVOGY, INC. (US) | 2015-03-26 | — | — | WO | claimed |
| US-20130042371-A1 | CHEMICALLY INDUCIBLE EXPRESSION OF BIOSYNTHETIC PATHWAYS | METABOLIX, INC. (US) | 2013-02-14 | — | — | US | claimed |
| EP-2183347-B1 | IMPROVEMENTS RELATING TO PERFUMES | UNILEVER PLC (GB) | 2012-04-18 | — | — | EP | claimed |
| US-20100196974-A1 | Chemically Inducible Expression of Biosynthetic Pathways | METABOLIX, INC. | 2010-08-05 | — | — | US | claimed |
| EP-1098962-B1 | DIACYLGLYCEROL ACYL TRANSFERASE PROTEINS | CALGENE LLC (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1863916-A2 | CHEMICALLY INDUCIBLE EXPRESSION OF BIOSYNTHETIC PATHWAYS | Metabolix, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20070067869-A1 | Chemically inducible expression of biosynthetic pathways | METABOLIX, INC. | 2007-03-22 | — | — | US | claimed |
| WO-2006101983-A2 | CHEMICALLY INDUCIBLE EXPRESSION OF BIOSYNTHETIC PATHWAYS | METABOLIX, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-0952836-B1 | Use of sulphoquinovosyldiacylglycerols for the treatment of inflammatory skin diseases | SCOTIA LIPIDTEKNIK AB (SE) | 2004-12-08 | — | — | EP | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| JP-2002533379-A | — | — | 2002-10-08 | — | — | JP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0498487-B1 | Improvements in edible fats | UNILEVER NV (NL) | 1995-04-26 | — | — | EP | claimed |
| EP-0498487-A1 | Improvements in edible fats | UNILEVER N.V. (NL) | 1992-08-12 | — | — | EP | claimed |
| US-20240216381-A1 | Px-cholorogenic Acid Comps | PX ING LLC (US) | 2024-07-04 | — | — | US | disclosed |
| EP-0037583-A1 | Method of fluorometrically measuring the activity of fat-degrading enzymes and means for carrying out the method | KSV-Chemicals Oy (FI) | 1981-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216381-A1 | Px-cholorogenic Acid Comps | CHAT, HCRTR1, PYGB | LPAR1 251/4885LPAR3 689/4885LPAR2 562/4885 |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | LPAR1 1227/4885LPAR3 2057/4885LPAR2 2143/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | LPAR1 990/4885LPAR3 1911/4885LPAR2 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.